AML gilteritinib treatment approved by the European Commission
XospataTM (gilteritinib) has been approved as a monotherapy for patients…
XospataTM (gilteritinib) has been approved as a monotherapy for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.